News & Updates

Show Multimedia Only

Novel thyroid hormone receptor β agonist shows promise in MASH

19 Sep 2026

Treatment with the thyroid hormone receptor β agonist ALG-055009 appears to yield substantial reductions in liver fat with no relevant safety issues in patients with metabolic dysfunction-associated steatohepatitis (MASH), according to a phase IIa study.

Novel thyroid hormone receptor β agonist shows promise in MASH

19 Sep 2026

Impaired glycoRNA expression may signal liver injury in patients with MASLD

17 Sep 2026

Glycosylated noncoding small RNAs (glycoRNAs) are present in human hepatocytes and liver tissues, showing a dysregulated expression in experimental steatosis models and in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), a study has found.

Impaired glycoRNA expression may signal liver injury in patients with MASLD

17 Sep 2026

Long-term bulevirtide treatment safe, effective for chronic hepatitis D

17 Sep 2026 by

Treatment with bulevirtide monotherapy for up to 144 weeks is safe, well tolerated, and effective in patients with chronic hepatitis D (CHD), a study has shown.

Long-term bulevirtide treatment safe, effective for chronic hepatitis D

17 Sep 2026

SGLT-2 inhibitors may avert portal hypertensive complications, death in cirrhosis patients

14 Sep 2026

Use of SGLT-2 inhibitors among patients with cirrhosis helps prevent portal hypertensive complications and improve survival, suggests a study.

SGLT-2 inhibitors may avert portal hypertensive complications, death in cirrhosis patients

14 Sep 2026

French study highlights atezolizumab–bevacizumab benefit in HCC

08 Sep 2026 by

Four-year updates from the CHIEF study show a durable survival benefit with atezolizumab plus bevacizumab in individuals with advanced hepatocellular carcinoma (HCC).

French study highlights atezolizumab–bevacizumab benefit in HCC

08 Sep 2026

Sleeve gastrectomy an important option for treating teens with severe obesity, MASLD

07 Sep 2026 by

For adolescents with severe obesity and metabolic dysfunction–associated steatotic liver disease (MASLD), vertical sleeve gastrectomy yields greater improvements in histologic and cardiometabolic outcomes compared with comprehensive lifestyle intervention, as shown in a single-centre, nonrandomized cohort study.

Sleeve gastrectomy an important option for treating teens with severe obesity, MASLD

07 Sep 2026

Semaglutide works wonders in MASH, MASLD

02 Sep 2026

Use of semaglutide results in steatohepatitis resolution and improved biochemical and imaging markers among patients with metabolic dysfunction-associated steatotic liver disease (MASLD), results of a meta-analysis have shown.

Semaglutide works wonders in MASH, MASLD

02 Sep 2026

Weight loss medications rarely prescribed in patients with MASLD: study

01 Sep 2026

A survey conducted prior to resmetirom approval reports low rates of weight loss medication prescription due to low comfort potentially from lack of education despite strong beliefs that these drugs can benefit patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Weight loss medications rarely prescribed in patients with MASLD: study

01 Sep 2026

Tenofovir-sparing ART carries HBV risks

31 Aug 2026 by

Discontinuing tenofovir in antiretroviral therapy (ART) may expose people living with HIV to hepatitis B virus (HBV)-related risks, including reactivation in those previously exposed and infection in those who are susceptible, according to a systematic review and meta-analysis.

Tenofovir-sparing ART carries HBV risks

31 Aug 2026

Hepatic response to fructose altered in patients with MASLD

24 Aug 2026

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) show clear patterns of change in phosphate metabolites following oral fructose consumption, suggesting differences in hepatic metabolic response, according to a study.

Hepatic response to fructose altered in patients with MASLD

24 Aug 2026

News & Updates

Showing Hepatology articles

Showing

Specialty:

Novel thyroid hormone receptor β agonist shows promise in MASH

Novel thyroid hormone receptor β agonist shows promise in MASH

Impaired glycoRNA expression may signal liver injury in patients with MASLD

Impaired glycoRNA expression may signal liver injury in patients with MASLD

Long-term bulevirtide treatment safe, effective for chronic hepatitis D

Long-term bulevirtide treatment safe, effective for chronic hepatitis D

SGLT-2 inhibitors may avert portal hypertensive complications, death in cirrhosis patients

SGLT-2 inhibitors may avert portal hypertensive complications, death in cirrhosis patients

French study highlights atezolizumab–bevacizumab benefit in HCC

French study highlights atezolizumab–bevacizumab benefit in HCC

Sleeve gastrectomy an important option for treating teens with severe obesity, MASLD

Sleeve gastrectomy an important option for treating teens with severe obesity, MASLD

Semaglutide works wonders in MASH, MASLD

Semaglutide works wonders in MASH, MASLD

Weight loss medications rarely prescribed in patients with MASLD: study

Weight loss medications rarely prescribed in patients with MASLD: study

Tenofovir-sparing ART carries HBV risks

Tenofovir-sparing ART carries HBV risks

Hepatic response to fructose altered in patients with MASLD

Hepatic response to fructose altered in patients with MASLD